Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potential Access the Akari CEO Corner …
Press Release
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the “What This Means” …
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- …
Akari Therapeutics Announces $5.5 Million Private Placement Offering
TAMPA, FL and LONDON – May 21, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with …
[Read more...] about Akari Therapeutics Announces $5.5 Million Private Placement Offering
Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here TAMPA, …
[Read more...] about Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
